dRAST provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture in as low as 4 hours; reducing time to results by up to 2 days compared to conventional method. The rapid results allow for earlier optimization of antibiotics in critically-ill patients with bloodstream infections and sepsis.